Rock Creek Group, LP Uni Qure N.V. Transaction History

Rock Creek Group, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$26.01 - $38.22 $422,662 - $621,075	-16,250 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$29.97 - $37.17 $487,012 - $604,012	16,250 New	16,250 $501,000
Q2 2020 Aug 13, 2020	SELL	$45.06 - $67.74 $2.7 Million - $4.06 Million	-60,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $19,884 - $36,763	-497 Reduced 0.82%	60,000 $2.85 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $18,453 - $37,086	497 Added 0.83%	60,497 $4.34 Million

Q3 2019 Nov 13, 2019	BUY	$39.36 - $76.8 $787,200 - $1.54 Million	20,000 Added 50.0%	60,000 $2.36 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $2.11 Million - $3.29 Million	40,000 New	40,000 $3.13 Million

148

34.1M

1.07M

603K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $179M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Rock Creek Group, LP, based on Form 13F filings with the SEC.

Stay updated on Rock Creek Group, LP with notifications on news.